Yet, glycosylation differences may lead to selective splicing and masking of epitope binding sites, thereby reducing detection accuracy.40 Additionally, it is noteworthy that both CD133+/− cancer cells can initiate tumors, raising questions about the validity of current CSC biomarkers as true tumor-initiating cells.1029 Recent studies have also discovered that CSCs exhibit high plasticity, capable of phenotypic transitions under specific conditions. This evidence concerns the gene PROM1 and cancer.